Innovative Cellular Therapeutics Holdings Ltd 4
4 · Lyell Immunopharma, Inc. · Filed Jul 17, 2026
Research Summary
AI-generated summary of this filing
Lyell (LYEL) 10% Owner Sells 10 Shares
What Happened Innovative Cellular Therapeutics Holdings Ltd, listed as a 10% owner of Lyell Immunopharma (LYEL), reported a sale of 10 shares on July 16, 2026. The shares were sold at $13.73 each for a total proceeds of $137. This was a sale (routine disposition) rather than a purchase.
Key Details
- Transaction date: 2026-07-16; Filing date: 2026-07-17.
- Price and amount: 10 shares at $13.73 per share; total value $137.
- Shares owned after transaction: Footnote F1 shows 2,857,500 shares beneficially owned immediately prior to the trade; after selling 10 shares the holder beneficially owns 2,857,490 shares.
- Transaction type: Sale (open market or private sale as reported).
- No late-filing flag is indicated in the record provided.
Context This is an institutional 10% owner, not an individual executive — such holders are often investment entities and small disposals (10 shares, ~0.00035% of the prior stake) are typically routine and not a strong signal of management sentiment. The dollar amount is negligible relative to the holder's total position.
Insider Transaction Report
Form 4
Transactions
- Sale
Common Stock
[F1]2026-07-16$13.73/sh−10$137→ 2,857,490 total
Footnotes (1)
- [F1]Reflects 2,857,500 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 10 shares sold.
Signature
Innovative Cellular Therapeutics Holdings Limited
By: /s/ Lei Xiao
Name: Lei Xiao
Title: Chief Executive Officer|2026-07-17